ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

FHS
March 13, 2025
10:18 am

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Phase I Study Aims To Determine Optimum Oncolytic Virus Dose for Recurrent Astrocytoma

Credit: DR P. MARAZZI/SCIENCE PHOTO LIBRARY/Getty Images Henry Ford Health researchers have announced the initiation of a Phase I clinical trial to determine maximum tolerated

June 14, 2023

Could python farming be the next big thing in sustainable livestock production?

A study in Scientific Reports suggests that python farming could be a sustainable and efficient livestock alternative, showing promising growth rates and high production efficiency

May 20, 2024

Filament Health Announces signing of definitive agreement for convertible note financing, closing of $900,000 non-brokered private placement financing | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, is pleased to announce that, further to

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.